1018899-03-0

Basic information

• Product Name: β-L-Xylopyranoside, Methyl 5-C-[4-chloro-3-[(4-ethoxyphenyl)Methyl]phenyl]-1-thio-, 2,3,4-triacetate,(5S)-
• Synonyms: β-L-Xylopyranoside, Methyl 5-C-[4-chloro-3-[(4-ethoxyphenyl)Methyl]phenyl]-1-thio-, 2,3,4-triacetate,(5S)-;(2S,3S,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(Methylthio)tetrahydro-2H-pyran-3,4,5-triyl triacetate;acetic acid (2R,3S,4R,5S,6S)-4,5-diacetoxy-6-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-2-methylsulfanyl-tetrahydro-pyran-3 -yl ester
• CAS NO: 1018899-03-0
• Molecular Formula: C₂₇H₃₁ClO₈S
• Molecular Weight: 551.04824
• Mol File: 1018899-03-0.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 617.6±55.0 °C(Predicted)
• Appearance: /
• Density: 1.30±0.1 g/cm3(Predicted)
• CAS DataBase Reference: β-L-Xylopyranoside, Methyl 5-C-[4-chloro-3-[(4-ethoxyphenyl)Methyl]phenyl]-1-thio-, 2,3,4-triacetate,(5S)-(CAS DataBase Reference)
• NIST Chemistry Reference: β-L-Xylopyranoside, Methyl 5-C-[4-chloro-3-[(4-ethoxyphenyl)Methyl]phenyl]-1-thio-, 2,3,4-triacetate,(5S)-(1018899-03-0)
• EPA Substance Registry System: β-L-Xylopyranoside, Methyl 5-C-[4-chloro-3-[(4-ethoxyphenyl)Methyl]phenyl]-1-thio-, 2,3,4-triacetate,(5S)-(1018899-03-0)

Safety Data

• Hazardous Substances Data: 1018899-03-0(Hazardous Substances Data)

Usage

General Description

"β-L-Xylopyranoside, Methyl 5-C-[4-chloro-3-[(4-ethoxyphenyl)Methyl]phenyl]-1-thio-, 2,3,4-triacetate,(5S)-" is a complex organic compound. It belongs to the group of compounds known as glycosyl compounds, which contain a carbohydrate or a glycosyl group. The specific structure of this compound includes an aromatic ring and an acetate group. It also features a chloro functional group, an ethoxy functional group, and a thiol functional group. The "S" in its name indicates that it has a particular stereoisomer form, specifically it is in the "S" (or sinister, from Latin) stereochemical configuration. β-L-Xylopyranoside, Methyl 5-C-[4-chloro-3-[(4-ethoxyphenyl)Methyl]phenyl]-1-thio-, 2,3,4-triacetate,(5S)- might be used in research, laboratory applications or in pharmaceutical drug development, but its specific uses, toxicity and safety measures generally depend on the particular context and they are not universally defined.

Upstream product

• 7647-01-0 hydrogenchloride 
• 6006-15-1 N,N-diethyl-N-isopropylamine 
• 584-08-7 potassium carbonate 
• 74-88-4 methyl iodide 
• 17314-32-8 tributyl(methylthio)stannane 
• 1103738-26-6 (2-chloro-5-iodo-phenyl)-(4-ethoxyphenyl)methanone 
• 1103738-29-9 1-chloro-2-(4-ethoxybenzyl)-4-iodobenzene 
• 1103738-30-2 (4-chloro-3-(4-ethoxybenzyl)phenyl)((3aS,5R,6S,6aS)-6-hydroxy-2,2-dimethyltetrahydrofuran[2,3-d][1,3]dioxolan-5-yl)methanone 
• 19094-56-5 2-chloro-5-iodobenzoic acid 
• 281652-58-2 2-chloro-5-iodobenzoylchloride 
• 1018899-04-1 (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxybenzyl)phenyl]-6-(methylsulfanyl)tetrahydro-2-H-pyran-3,4,5-triol 

Downstream Products

• 1018899-04-1 (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxybenzyl)phenyl]-6-(methylsulfanyl)tetrahydro-2-H-pyran-3,4,5-triol 

Relevant articles and documents

Process development of sotagliflozin, a dual inhibitor of sodium- Glucose cotransporter-1/2 for the treatment of diabetes

The development of an efficient manufacturing process for sotagliflozin (LX4211), a dual inhibitor of sodium- glucose cotransporter-1/2 (SGLT-1/2) for the treatment of diabetes, is described. Sotagliflozin features five contiguous chiral centers on the carbohydrate core flanked by a thioether group and a biaryl moiety. Three chiral centers are obtained from the starting material L-xylose, while the other two were established (or modified) via three highly stereoselective transformations: Luche reduction (dr: 97/3), dynamic kinetic resolution of anomeric hemiacetal (dr: 95/5), and Lewis acid-promoted thiolation (dr: 1000/ 1). Global deprotection of the resulting penultimate intermediate with catalytic sodium methoxide followed by recrystallization furnishes sotagliflozin. The longest linear sequence consists of 10 steps from L-xylose with an overall yield of 40%. This process has been performed on multi-hundred kilogram batches to satisfy the drug substance development demands.

Radical Dehydroxymethylative Fluorination of Carbohydrates and Divergent Transformations of the Resulting Reverse Glycosyl Fluorides

A mild and convenient method for the synthesis of reverse glycosyl fluorides (RGFs) has been developed that is based on the silver-promoted radical dehydroxymethylative fluorination of carbohydrates. A salient feature of the reaction is that furanoid and pyranoid carbohydrates furnish structurally diverse RGFs bearing a wide variety of functional groups in good to excellent yields. Intramolecular hydrogen atom transfer experiments revealed that the reaction involves an underexploited radical fluorination that proceeds via β-fragmentation of sugar-derived primary alkoxyl radicals. Structurally divergent RGFs were obtained by catalytic C?F bond activation, and our method thus offers a concise and efficient strategy for the synthesis of reverse glycosides by late-stage diversification of RGFs. The potential of this method is showcased by the preparation and diversification of sotagliflozin, leading to the discovery of a promising SGLT2 inhibitor candidate.

Glucopyranosyl derivative and application thereof in medicine

The invention relates to a glucopyranosyl derivative as a sodium-dependent glucose transporter (SGLT) inhibitor, a pharmaceutical composition containing the derivative and an application thereof in medicine, and in particular to the glucopyranosyl derivative as shown in a formula (I) or a pharmaceutically acceptable salt or all stereisomers thereof, or use of the pharmaceutical composition containing the derivative and the derivative and the pharmaceutical composition for preparing medicines treating diabetes and diabetes related diseases.